Immunomodulators Market, by Product Type (Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, and Others), Immunostimulants (Vaccines, Antibodies, and Others)), by Application (Oncology, Respiratory, HIV, and Others), by End User

Immunomodulators Market, by Product Type (Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, and Others), Immunostimulants (Vaccines, Antibodies, and Others)), by Application (Oncology, Respiratory, HIV, and Others), by End User (Hospitals, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Immunomodulators are medications that either stimulate or inhibit the immune system. They affect the immunological response by modifying the immune system. Immunomodulators function by lowering the amount of antibodies produced in response to foreign antigens, which stimulate immune reactions. Immunosuppressants and immunostimulants are two different categories of immunomodulators. Corticosteroids, thymosin, and immunoglobulins are a few of the Immunomodulators. Cancer, infection, asthma, and other disorders are treated with these drugs. Immunosuppressants are commonly used to avoid organ rejection during various transplant procedures. Immunostimulants could possibly be utilized to treat HIV and cancer.
Inflammatory bowel disease (IBD), notably ulcerative colitis (UC), and Crohn's disease (CD), can be effectively treated with immunomodulators. Immunomodulators are also commonly employed in organ transplants and the treatment of autoimmune illnesses. Steroids are sometimes taken in conjunction with immunomodulators to speed up the effect of immunomodulators. They are used in contemporary vaccination formulations and play an important role in pharmaceuticals. Immunomodulation focuses on manipulating the immune system to reduce infections and other negative health impacts while maintaining precise control to avoid problems such as frequent and recurrent pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, and others. Simultaneously, efforts to improve animal and human health by suppressive or potentiating measures are made.
Market Dynamics
The rising prevalence of autoimmune illnesses such as rheumatoid arthritis, systemic lupus erythematosus (Lupus), juvenile rheumatoid arthritis, inflammatory bowel arthritis, Psoriatic arthritis, and others is a major contributor to the global immunomodulators market's expansion. For instance, according to the National Institutes of Health, up to 23.5 million Americans (almost 7% of the population) had an autoimmune disease in 2017, resulting in a larger patient pool and, in turn, a larger market.
Key features of the study:
This report provides in-depth analysis of the immunomodulators market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global Immunomodulators market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immunomodulators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the immunomodulators market
Detailed Segmentation:
Global Immunomodulators Market, By Product Type:
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
Global Immunomodulators Market, By Application:
Oncology
Respiratory
HIV
Others
Global Immunomodulators Market, By End User:
Hospitals
Clinics
Others
Global Immunomodulators Market, By Region:
North America
By Product Type
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
By Application
Oncology
Respiratory
HIV
Others
By End User
Hospitals
Clinics
Others
By Country
U.S.
Canada
Latin America
By Product Type
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
By Application
Oncology
Respiratory
HIV
Others
By End User
Hospitals
Clinics
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
By Application
Oncology
Respiratory
HIV
Others
By End User
Hospitals
Clinics
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
By Application
Oncology
Respiratory
HIV
Others
By End User
Hospitals
Clinics
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
By Application
Oncology
Respiratory
HIV
Others
By End User
Hospitals
Clinics
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Immunosuppressants
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
By Application
Oncology
Respiratory
HIV
Others
By End User
Hospitals
Clinics
Others
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
F. Hoffmann-La Roche Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Biogen Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG
Amgen, Inc.
Bristol-Myers Squibb Company
Merck Sharp & Dohme Corp.
Eli Lilly and Company
Abbott Laboratories
Johnson & Johnson
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.